422 related articles for article (PubMed ID: 28571554)
1. Methotrexate in the Treatment of Psoriasis and Rheumatoid Arthritis: Mechanistic Insights, Current Issues and Novel Delivery Approaches.
Rajitha P; Biswas R; Sabitha M; Jayakumar R
Curr Pharm Des; 2017; 23(24):3550-3566. PubMed ID: 28571554
[TBL] [Abstract][Full Text] [Related]
2. A hyaluronic acid-methotrexate conjugate for targeted therapy of rheumatoid arthritis.
Shin JM; Kim SH; Thambi T; You DG; Jeon J; Lee JO; Chung BY; Jo DG; Park JH
Chem Commun (Camb); 2014 Jul; 50(57):7632-5. PubMed ID: 24893961
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate Aspasomes Against Rheumatoid Arthritis: Optimized Hydrogel Loaded Liposomal Formulation with In Vivo Evaluation in Wistar Rats.
Ghosh S; Mukherjee B; Chaudhuri S; Roy T; Mukherjee A; Sengupta S
AAPS PharmSciTech; 2018 Apr; 19(3):1320-1336. PubMed ID: 29340978
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate and cardiovascular risk in rheumatic diseases:A comprehensive review.
Verhoeven F; Prati C; Chouk M; Demougeot C; Wendling D
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1105-1112. PubMed ID: 34006152
[No Abstract] [Full Text] [Related]
5. Methotrexate: a gold standard for treatment of rheumatoid arthritis.
Shinde CG; Venkatesh MP; Kumar TM; Shivakumar HG
J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):351-8. PubMed ID: 25322199
[TBL] [Abstract][Full Text] [Related]
6. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis.
Abolmaali SS; Tamaddon AM; Dinarvand R
Cancer Chemother Pharmacol; 2013 May; 71(5):1115-30. PubMed ID: 23292116
[TBL] [Abstract][Full Text] [Related]
7. In brief: otrexup--a single-use auto-injector formulation of methotrexate.
Med Lett Drugs Ther; 2014 Mar; 56(1439):28. PubMed ID: 24691150
[No Abstract] [Full Text] [Related]
8. New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis.
Schiff M; Jaffe J; Freundlich B; Madsen P
Expert Rev Med Devices; 2014 Sep; 11(5):447-55. PubMed ID: 24934630
[TBL] [Abstract][Full Text] [Related]
9. A novel indomethacin/methotrexate/MMP-9 siRNA in situ hydrogel with dual effects of anti-inflammatory activity and reversal of cartilage disruption for the synergistic treatment of rheumatoid arthritis.
Yin N; Tan X; Liu H; He F; Ding N; Gou J; Yin T; He H; Zhang Y; Tang X
Nanoscale; 2020 Apr; 12(15):8546-8562. PubMed ID: 32243486
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Clowse ME; Feldman SR; Isaacs JD; Kimball AB; Strand V; Warren RB; Xibillé D; Chen Y; Frazier D; Geier J; Proulx J; Marren A
Drug Saf; 2016 Aug; 39(8):755-62. PubMed ID: 27282428
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data.
De Vecchis R; Baldi C; Palmisani L
Anatol J Cardiol; 2016 Jan; 16(1):2-9. PubMed ID: 26467356
[TBL] [Abstract][Full Text] [Related]
12. Nanostructured lipid carrier mediates effective delivery of methotrexate to induce apoptosis of rheumatoid arthritis via NF-κB and FOXO1.
Garg NK; Tyagi RK; Singh B; Sharma G; Nirbhavane P; Kushwah V; Jain S; Katare OP
Int J Pharm; 2016 Feb; 499(1-2):301-320. PubMed ID: 26768725
[TBL] [Abstract][Full Text] [Related]
13. Microemulsions mediated effective delivery of methotrexate hydrogel: more than a tour de force in psoriasis therapeutics.
Amarji B; Garg NK; Singh B; Katare OP
J Drug Target; 2016; 24(2):147-60. PubMed ID: 26204326
[TBL] [Abstract][Full Text] [Related]
14. Insights on methotrexate in psoriatic disease.
Greb JE; Goldminz AM; Gottlieb AB
Clin Immunol; 2016 Nov; 172():61-64. PubMed ID: 27455859
[TBL] [Abstract][Full Text] [Related]
15. Synergistically engineered nanotransethosomes for co-delivery of methotrexate and baicalin for enhanced transdermal delivery against rheumatoid arthritis: formulation, characterisation and in vivo pharmacodynamic evaluation.
Adin SN; Gupta I; Aqil M; Mujeeb M; Najmi AK
J Drug Target; 2024 Jul; 32(6):707-723. PubMed ID: 38652489
[No Abstract] [Full Text] [Related]
16. Endogenous inspired biomineral-installed hyaluronan nanoparticles as pH-responsive carrier of methotrexate for rheumatoid arthritis.
Alam MM; Han HS; Sung S; Kang JH; Sa KH; Al Faruque H; Hong J; Nam EJ; Kim IS; Park JH; Kang YM
J Control Release; 2017 Apr; 252():62-72. PubMed ID: 28288894
[TBL] [Abstract][Full Text] [Related]
17. Current understanding of rheumatoid arthritis therapy.
Colmegna I; Ohata BR; Menard HA
Clin Pharmacol Ther; 2012 Apr; 91(4):607-20. PubMed ID: 22357455
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate.
Amital H; Arnson Y; Chodick G; Shalev V
Rheumatology (Oxford); 2009 Sep; 48(9):1107-10. PubMed ID: 19578136
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate revisited: considerations for subcutaneous administration in RA.
Jay R
Clin Rheumatol; 2015 Feb; 34(2):201-5. PubMed ID: 25433918
[TBL] [Abstract][Full Text] [Related]
20. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
Yamaguchi Y; Yamamoto K
Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
